Phio Pharmaceuticals Corp.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
411 SWEDELAND ROAD, KING OF PRUSSIA, PA, 19406
Mailing Address
411 SWEDELAND ROAD, KING OF PRUSSIA, PA, 19406
Phone
(508) 767-3861
Fiscal Year End
1231
EIN
453215903
Financial Overview
FY2025
-$7.15M
Net Income
$21.49M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 8, 2026 | View on SEC |
| 424B5 Prospectus supplement | April 8, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Developing new cancer immunotherapies using proprietary INTASYL™ technology.
- Resilience in cybersecurity, with no major security incidents in the past three years.
Insider Trading
BUY
1 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.